Ou Tangjing(R) (Embagliflozin Tablets) became the first and currently the only SGLT-2 inhibitor approved in China for the treatment of adult patients with symptomatic chronic heart failure (regardless of the patient's ejection fraction).

On August 30, 2022, Boehringer Ingelheim and Eli Lilly jointly announced that the new indication of its SGLT2 inhibitor Ou Tangjing® (generic name: empagliflozin tablets) under the Diabetes Alliance has been approved by the National Medical Products Administration of China.

A common and incurable, life-threatening disease, heart failure is a severe and terminal stage of various cardiac diseases characterized by dyspnea, fatigue, and fluid retention (pulmonary congestion, systemic congestion, and peripheral edema) etc.

       The approval of the new indication of Otolide® is based on the EMPEROR-Preserved global pivotal Phase III clinical trial in the EMPOWER heart failure study

       Professor Zhang Jian, principal investigator of the EMPEROR-Preserved study in China, said: "The biggest cardiovascular disease challenge we face in the 21st century is heart failure.

       Ji Liwen, President and General Manager of Eli Lilly China, said: "The approval of the new indication marks the achievement of another important milestone for Autangjing®, so far Autangjing® has covered the two major therapeutic areas of diabetes and heart failure, and laid a solid foundation Important therapeutic status

       Dr.

       About heart failure

       Heart failure is a progressive, debilitating, and potentially life-threatening condition in which fluid builds up (congestion) in the lungs and peripheral tissues when the heart cannot supply enough circulation to meet the body's need for oxygenated blood or to increase blood volume occurs when